In Taiwan’s drug registration process, the TFDA evaluates efficacy through clinical trial data that demonstrates the drug’s ability to produce the desired therapeutic effect. The review includes Phase II and Phase III trial results, focusing on measurable outcomes. If foreign data is submitted, bridging studies may be required to confirm relevance for the local population.